Literature DB >> 11882003

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.

Svetlana S Printsevskaya1, Andrey Y Pavlov, Evgenia N Olsufyeva, Elena P Mirchink, Elena B Isakova, Marina I Reznikova, Robert C Goldman, Arthur A Branstrom, Eugene R Baizman, Clifford B Longley, Ferenc Sztaricskai, Gyula Batta, Maria N Preobrazhenskaya.   

Abstract

Des-(N-methyl-D-leucyl)eremomycin was obtained by Edman degradation of eremomycin. Derivatives with a hydrophobic substituent at the exterior of the molecule were then synthesized, and their antibacterial activities were compared with similar derivatives of eremomycin. Comparison of derivatives of eremomycin containing the n-decyl or p-(p-chlorophenyl)benzyl substituent in the eremosamine moiety (N') and n-decyl or p-(p-chlorophenyl)benzylamides with similar derivatives of eremomycin possessing the damaged peptide core (a defective binding pocket) showed that compounds of both types are almost equally active against glycopeptide-resistant strains of enterococci (GRE), whereas eremomycin derivatives are more active against staphylococci. Hydrophobic 7d-alkylaminomethylated derivatives of eremomycin (9, 10) demonstrated similar antibacterial properties. Since the basic mode of action of glycopeptide antibiotics involves binding to cell wall intermediates terminating in -D-Ala-D-Ala and this interaction is seriously decreased in the hexapeptide derivatives (lacking the critical N-methyl-D-leucine), we suggest that these hydrophobic derivatives may inhibit peptidoglycan synthesis in the absence of dipeptide binding. NMR binding experiments using Ac-D-Ala-D-Ala show that binding constants of these hexapeptide derivativies are decreased in comparison with the corresponding heptapeptides with intact binding pocket. This is in agreement with the decreased biological activity of the hexapeptide derivatives against vancomycin-sensitive strains in comparison with the activity of parent compounds. Binding to the lactate cell wall analogue Ac-D-Ala-D-Lac with decylamide of eremomycin 8 was not observed, demonstrating that the interaction with this target in GRE does not occur. While hydrophobic glycopeptide derivatives retain the ability to inhibit the synthesis of peptidoglycan in manner of natural glycopeptides, biochemical investigation supports the hypothesis that they inhibit the transglycosylase stage of bacterial peptidoglycan biosynthesis even in the absence of dipeptide or depsipeptide binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882003     DOI: 10.1021/jm010460i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-d-Ala-d-Ala Segment of the Peptidoglycan Pentapeptide Stem.

Authors:  James Chang; Hongyu Zhou; Maria Preobrazhenskaya; Peng Tao; Sung Joon Kim
Journal:  Biochemistry       Date:  2016-06-07       Impact factor: 3.162

3.  Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus.

Authors:  Sung Joon Kim; Manmilan Singh; Shasad Sharif; Jacob Schaefer
Journal:  Biochemistry       Date:  2017-03-03       Impact factor: 3.162

4.  Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance.

Authors:  Sung Joon Kim; Lynette Cegelski; Maria Preobrazhenskaya; Jacob Schaefer
Journal:  Biochemistry       Date:  2006-04-25       Impact factor: 3.162

Review 5.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Vancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus.

Authors:  Sung Joon Kim; Shigeru Matsuoka; Gary J Patti; Jacob Schaefer
Journal:  Biochemistry       Date:  2008-02-27       Impact factor: 3.162

7.  Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Authors:  Jan Balzarini; Els Keyaerts; Leen Vijgen; Herman Egberink; Erik De Clercq; Marc Van Ranst; Svetlana S Printsevskaya; Eugenia N Olsufyeva; Svetlana E Solovieva; Maria N Preobrazhenskaya
Journal:  Antiviral Res       Date:  2006-04-06       Impact factor: 5.970

Review 8.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

9.  Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry.

Authors:  Maria N Preobrazhenskaya; Eugenia N Olsufyeva
Journal:  Antiviral Res       Date:  2006-05-06       Impact factor: 5.970

10.  Anti-influenza virus activity and structure-activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains.

Authors:  Lieve Naesens; Evelien Vanderlinden; Erzsébet Roth; József Jeko; Graciela Andrei; Robert Snoeck; Christophe Pannecouque; Eszter Illyés; Gyula Batta; Pál Herczegh; Ferenc Sztaricskai
Journal:  Antiviral Res       Date:  2009-02-05       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.